Hemab Therapeutics Holdings, Inc. Common Stock (COAG) vs Maze Therapeutics, Inc. (MAZE)

A side-by-side comparison of Hemab Therapeutics Holdings, Inc. Common Stock and Maze Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Hemab Therapeutics Holdings, Inc. Common Stock logo
COAG
Hemab Therapeutics Holdings, Inc. Common Stock
$1.33B
$28.44HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT
Maze Therapeutics, Inc. logo
MAZE
Maze Therapeutics, Inc.
$1.46B
$26.41HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT

Total return — COAG vs MAZE

growth of $100 · dividends reinvested · last 1y
COAG -10.0% (-10.0%/yr)MAZE -2.7% (-2.7%/yr)MAZE compounded faster over this window
80100120140160Start $100$90$97
COAG MAZE

COAG vs MAZE: by the numbers

  • •MAZE is the larger company ($1.46B vs $1.33B market cap).
  • •Both run net losses; COAG's is the smaller (0.00% vs -667.95% net margin).

Metrics side by side

Valuation

MetricCOAGMAZE
P/S ratioN/A73.07
P/B ratio2.923.23

Profitability

MetricCOAGMAZE
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%-667.95%
ROEN/A-29.48%
ROIC-38.09%-28.63%

Go deeper

Full COAG analysisFull MAZE analysisInteractive comparison tool

Dig into the metrics

Hemab Therapeutics Holdings, Inc. Common Stock ROEMaze Therapeutics ROEHemab Therapeutics Holdings, Inc. Common Stock operating marginMaze Therapeutics operating marginHemab Therapeutics Holdings, Inc. Common Stock revenue growthMaze Therapeutics revenue growthHemab Therapeutics Holdings, Inc. Common Stock free cash flowMaze Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.